Group B Streptococcus Market
Group B Streptococcus Market Infographics

Group B Streptococcus Market

A typical bacterium that is frequently seen in the intestines or lower genital tract is group B strep (streptococcus). In healthy individuals, the bacterium is mostly harmless; but, in neonates, it can result in the deadly sickness known as GBS.


Group B Streptococcus Epidemiology Insights (2022)

  • The Total Group B Streptococcus incident cases in the 7MM - ~227K cases in 2022
  • EU4 and the UK contributed ~20% of incident cases
  • Nearly 2 million pregnant women were estimated to have Group B Streptococcus colonization
  • Invasive type account for 22% of incident cases


Group B Streptococcus Epidemiology Segmentation in the 7MM from 2019 to 2040

  • Total Incident Cases
  • Type-specific Incident Cases
  • Age-specific Incident Cases of GBS by types
  • Number of Cases of GBS Colonization


Group B Streptococcus Market Insight (2022)

  • The Group B Streptococcus Market size in the 7MM was valued ~USD 194 million in 2022
  • The United States captured the largest market size for Group B Streptococcus among the 7MM regions


Group B Streptococcus Emerging Drugs and Key Companies

  • GBS-NN/NN2: Minervax ApS
  • GBS 6 (PF-06760805): Pfizer, and others